- Home
- DJCO vs GYRE Comparison
DJCO vs GYRE Comparison
Compare DJCO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJCO | GYRE |
|---|---|---|
| Founded | 1987 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.0M | 606.4M |
| IPO Year | 1995 | 2004 |
Fundamental Metrics
Financial Performance| Metric | DJCO | GYRE |
|---|---|---|
| Price | $575.10 | $5.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 26.8K | ★ 96.7K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,384,000.00 | $275,000.00 |
| Revenue This Year | N/A | $19.88 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $348.63 | $5.44 |
| 52 Week High | $674.75 | $9.42 |
Technical Indicators
Market Signals| Indicator | DJCO | GYRE |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 41.79 |
| Support Level | $552.74 | $5.74 |
| Resistance Level | $625.00 | $8.28 |
| Average True Range (ATR) | 23.96 | 0.29 |
| MACD | -3.28 | -0.08 |
| Stochastic Oscillator | 40.26 | 9.33 |
Price Performance
Historical ComparisonAbout DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.